Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ASP006
MIFTS: 71

Aspergillosis

Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Aspergillosis

About this section

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 57 12 73 20 58 54 42 3 44 15 17 70 32
Aspergillosis, Susceptibility to 57 29 13 6 39
Infection Due to Aspergillus 12

Characteristics:

Orphanet epidemiological data:

58
aspergillosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare infectious diseases


Sources

Summaries for Aspergillosis

About this section
GARD : 20 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to allergic bronchopulmonary aspergillosis and invasive aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Guaifenesin and Phenylpropanolamine have been mentioned in the context of this disorder. Affiliated tissues include lung, bone marrow and myeloid, and related phenotypes are cough and positive blood 1,3 beta glucan test

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM® : 57 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079) (Updated 20-May-2021)

MedlinePlus : 42 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 73 Aspergillosis is the name given to a wide variety of diseases caused by fungal infections from species... more...

Sources

Related Diseases for Aspergillosis

About this section

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1127)
# Related Disease Score Top Affiliating Genes
1 allergic bronchopulmonary aspergillosis 33.0 SFTPD MBL2 IL5 IL4 IL10 IFNG
2 invasive aspergillosis 32.5 TLR4 TLR2 SFTPD PTX3 MBL2 IL10
3 hypereosinophilic syndrome 31.6 IL5 IL4 IL10 IFNG
4 bronchiectasis 31.5 TNF TLR2 MBL2 IL1B ELANE CFTR
5 mucormycosis 31.5 IFNG CSF3 CLEC7A CCR6
6 neutropenia 31.5 TNF MBL2 IL1B IL10 ELANE CSF3
7 graft-versus-host disease 31.3 TNF IL1B IL10 IFNG
8 chronic granulomatous disease 31.2 TNF TLR9 IL1B IFNG ELANE CSF3
9 eosinophilic pneumonia 31.1 SFTPD IL5 IL4
10 candidiasis 31.1 TNF TLR4 TLR2 MBL2 IL4 IL1B
11 rhinitis 31.1 TNF IL5 IL4 IL10 IFNG
12 pulmonary fibrosis 31.1 SFTPD IL1B ELANE CCL3
13 covid-19 31.0 TNF TLR4 IL4 IL1B
14 pulmonary tuberculosis 31.0 TNF TLR2 MBL2 IL4 IL10 IFNG
15 endophthalmitis 31.0 TNF TLR2 IL1B
16 endocarditis 30.9 TNF TLR2 IL10 IFNG
17 ige responsiveness, atopic 30.9 IL5 IL4 IL10 IFNG
18 adult respiratory distress syndrome 30.9 TNF SFTPD IL1B IL10 ELANE CSF3
19 vasculitis 30.9 TNF PTX3 MBL2 ELANE
20 purpura 30.9 TNF IL4 IL10 IFNG
21 severe acute respiratory syndrome 30.9 TNF TLR4 MBL2 IL1B IL10 IFNG
22 cystic fibrosis 30.9 TNF TLR4 TLR2 SFTPD MBL2 IL5
23 liver cirrhosis 30.8 TNF TLR4 TLR2 IL1B IL10 IFNG
24 fungal infectious disease 30.8 TNF TLR4 TLR2 IL5 IL4 IL1B
25 acute graft versus host disease 30.8 TNF IL4 IL10 IFNG CSF3
26 leukemia, acute myeloid 30.8 TNF IL4 IL1B IL10 CSF3 CSF1
27 toxic shock syndrome 30.8 TNF TLR4 TLR2 IL4 IL1B IL10
28 myelodysplastic syndrome 30.8 TNF IL1B IL10 IFNG CSF3 CSF1
29 cryptococcosis 30.8 TNF MBL2 IL4 IL10 IFNG CLEC7A
30 churg-strauss syndrome 30.7 TNF IL5 IL1B IL10
31 chronic graft versus host disease 30.7 IL10 IFNG
32 osteomyelitis 30.7 TNF TLR4 TLR2 IL4 IL1B IL10
33 pneumoconiosis 30.7 TNF IL4 IL1B IL10
34 acquired immunodeficiency syndrome 30.7 TNF IL1B IL10 IFNG CCR6 CCL3
35 actinomycosis 30.7 TNF IL4 IL1B IL10
36 allergic rhinitis 30.7 IL5 IL4 IL10 IFNG
37 bronchitis 30.7 TNF TLR4 TLR2 IL5 IL4 IL1B
38 enterocolitis 30.7 TNF TLR4 IL10
39 histoplasmosis 30.6 TNF IFNG CLEC7A CCR6
40 respiratory failure 30.6 TNF TLR4 SFTPD PTX3 IL5 IL1B
41 allergic asthma 30.6 TLR4 TLR2 IL5 IL4 IL10 IFNG
42 bronchopneumonia 30.6 TNF TLR4 IL1B IL10 ELANE CCL3
43 pneumocystosis 30.6 TNF SFTPD CSF3 CLEC7A CCR6
44 chronic eosinophilic pneumonia 30.6 IL5 CSF3 CCL3
45 sarcoidosis 1 30.6 TNF SFTPD IL1B IFNG CCR6 CCL3
46 spondylitis 30.6 TNF IL1B IL10 IFNG CCR6
47 pericarditis 30.6 TNF IL1B IFNG
48 penicilliosis 30.6 IFNG CLEC7A
49 bronchiolitis obliterans 30.6 TNF TLR4 SFTPD IL10 IFNG
50 coccidioidomycosis 30.5 TLR4 MBL2 CLEC7A CCR6

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):


Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:



Diseases related to Aspergillosis
Sources

Symptoms & Phenotypes for Aspergillosis

About this section

Human phenotypes related to Aspergillosis:

58 31 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
2 positive blood 1,3 beta glucan test 58 31 hallmark (90%) Very frequent (99-80%) HP:0020153
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
5 hemoptysis 58 31 frequent (33%) Frequent (79-30%) HP:0002105
6 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
7 neutropenia 58 31 frequent (33%) Frequent (79-30%) HP:0001875
8 eosinophilia 58 31 frequent (33%) Frequent (79-30%) HP:0001880
9 chronic lung disease 58 31 frequent (33%) Frequent (79-30%) HP:0006528
10 abnormality on pulmonary function testing 58 31 frequent (33%) Frequent (79-30%) HP:0030878
11 ground-glass opacification on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025179
12 parenchymal consolidation 58 31 frequent (33%) Frequent (79-30%) HP:0032177
13 visual impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000505
14 sinusitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000246
15 hepatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012115
16 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
17 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
18 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
19 abnormality of the kidney 58 31 occasional (7.5%) Occasional (29-5%) HP:0000077
20 keratitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000491
21 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
22 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
23 hematological neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0004377
24 pleuritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002102
25 diffuse reticular or finely nodular infiltrations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002207
26 dacryocystitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000620
27 localized skin lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0011355
28 ocular pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0200026
29 abnormal esophagus morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002031
30 nasal obstruction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001742
31 rhinorrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0031417
32 hypersensitivity pneumonitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006516
33 invasive pulmonary aspergillosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0020103
34 increased circulating ige level 31 occasional (7.5%) HP:0003212
35 chronic pulmonary obstruction 31 occasional (7.5%) HP:0006510
36 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
37 abnormality of the ribs 58 31 very rare (1%) Very rare (<4-1%) HP:0000772
38 stroke 58 31 very rare (1%) Very rare (<4-1%) HP:0001297
39 abnormality of the vertebral column 58 31 very rare (1%) Very rare (<4-1%) HP:0000925
40 meningitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001287
41 osteomyelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002754
42 intracranial hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0002170
43 pleural effusion 58 31 very rare (1%) Very rare (<4-1%) HP:0002202
44 abnormality of long bone morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0011314
45 bronchiectasis 58 31 very rare (1%) Very rare (<4-1%) HP:0002110
46 functional motor deficit 58 31 very rare (1%) Very rare (<4-1%) HP:0004302
47 periorbital fullness 58 31 very rare (1%) Very rare (<4-1%) HP:0000629
48 vitritis 58 31 very rare (1%) Very rare (<4-1%) HP:0011531
49 abnormality of the skull base 58 31 very rare (1%) Very rare (<4-1%) HP:0002693
50 seizure 31 very rare (1%) HP:0001250

Clinical features from OMIM®:

614079 (Updated 20-May-2021)

UMLS symptoms related to Aspergillosis:


fever; pruritus

GenomeRNAi Phenotypes related to Aspergillosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCL3 CCR6 CLEC7A CSF1 CSF3 IL5

MGI Mouse Phenotypes related to Aspergillosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
2 immune system MP:0005387 10.28 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
3 homeostasis/metabolism MP:0005376 10.27 CCR6 CFTR CLEC7A CSF1 ELANE IFNG
4 digestive/alimentary MP:0005381 10.13 CFTR CLEC7A IFNG IL10 IL4 IL5
5 integument MP:0010771 9.96 CSF1 CSF3 ELANE IFNG IL10 IL1B
6 liver/biliary system MP:0005370 9.81 CFTR CSF1 IFNG IL10 IL4 IL5
7 neoplasm MP:0002006 9.56 ELANE IFNG IL10 IL1B IL5 TLR2
8 respiratory system MP:0005388 9.4 CFTR CLEC7A CSF1 IFNG IL10 IL4
Sources

Drugs & Therapeutics for Aspergillosis

About this section

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
3
Benralizumab Approved, Investigational Phase 4 1044511-01-4
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
7
Omalizumab Approved, Investigational Phase 4 242138-07-4
8
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
9 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
10 Antitussive Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Antiprotozoal Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Antibodies, Monoclonal Phase 4
15
Hydroxyitraconazole Phase 4 108222
16 Liposomal amphotericin B Phase 4
17 Anti-Bacterial Agents Phase 4
18 Amebicides Phase 4
19 Respiratory System Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Immunoglobulins Phase 4
22 Immunoglobulin E Phase 4
23 Immunoglobulins, Intravenous Phase 4
24 Anti-Allergic Agents Phase 4
25 Antibodies Phase 4
26
Isavuconazole Approved, Investigational Phase 3 241479-67-4
27
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 62924
28
deoxycholic acid Approved Phase 2, Phase 3 83-44-3 222528
29
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
30
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
31
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
34
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
35
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
36
Deflazacort Approved, Investigational Phase 2, Phase 3 14484-47-0
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
38
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
39
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
40 Formoterol Fumarate Phase 2, Phase 3
41 Micronutrients Phase 2, Phase 3
42 Trace Elements Phase 2, Phase 3
43 Nutrients Phase 2, Phase 3
44 Vitamins Phase 2, Phase 3
45 Calciferol Phase 2, Phase 3
46 Amphotericin B, deoxycholate drug combination Phase 2, Phase 3
47 Bronchodilator Agents Phase 2, Phase 3
48 Methylprednisolone Acetate Phase 2, Phase 3
49 glucocorticoids Phase 2, Phase 3
50 Antineoplastic Agents, Hormonal Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective，Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients Unknown status NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
5 A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
6 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
7 A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
8 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Completed NCT03731169 Phase 4 Standard of Care
9 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
10 Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis Recruiting NCT04108962 Phase 4 Fasenra, 30 Mg/mL Subcutaneous Solution
11 Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis Recruiting NCT04238884 Phase 4 Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
12 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
13 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
14 An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
15 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
16 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
17 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
18 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINEâ„¢) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
19 A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Unknown status NCT02440009 Phase 2, Phase 3 Itraconazole;Glucocorticoids
20 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
21 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
22 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
23 A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
24 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
25 Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
26 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
27 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole;Placebo
28 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
29 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
30 Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts Completed NCT00159822 Phase 2, Phase 3 Voriconazole
31 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
32 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
33 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
34 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
35 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
36 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
37 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
38 A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
39 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
40 A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant Completed NCT00001937 Phase 3 FK463;Fluconazole
41 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
42 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
43 A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis Recruiting NCT04824417 Phase 3 Itraconazole 200 mg;Voriconazole 200mg
44 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
45 A Randomized Controlled Trial of Deflazacort vs. Prednisolone in Acute-stage Allergic Bronchopulmonary Aspergillosis Recruiting NCT04227483 Phase 2, Phase 3 Deflazacort;Prednisolone
46 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis Recruiting NCT04442269 Phase 3 dupilumab;Placebo
47 Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients With Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (Single Aspergilloma Excluded) Recruiting NCT03656081 Phase 3 inhaled Ambisome®;inhaled placebo;Itraconazole
48 Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients Recruiting NCT04707703 Phase 3 Isavuconazonium Injection [Cresemba];Placebo
49 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Active, not recruiting NCT03471988 Phase 3 AK1820;Voriconazole
50 A Randomized Controlled Trial to Compare the Clinical Outcomes of Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis Active, not recruiting NCT03920527 Phase 3 Itraconazole 400 mg

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Caspofungin
Caspofungin acetate
Flucytosine
Itraconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
voriconazole

Cochrane evidence based reviews: aspergillosis

Sources

Genetic Tests for Aspergillosis

About this section

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 29 CLEC1A CLEC7A
Sources

Anatomical Context for Aspergillosis

About this section

MalaCards organs/tissues related to Aspergillosis:

40
Lung, Bone Marrow, Myeloid, Kidney, Brain, Skin, Liver
Sources

Publications for Aspergillosis

About this section

Articles related to Aspergillosis:

(show top 50) (show all 13556)
# Title Authors PMID Year
1
Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. 57 6 61
20807886 2010
2
Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. 6 57
29489751 2018
3
Toll-like receptor 4 polymorphisms and aspergillosis. 61 54 57
19202580 2009
4
Toll-like receptor 4 polymorphisms and aspergillosis. 61 54 57
19202579 2009
5
Toll-like receptor 4 polymorphisms and aspergillosis. 57 61 54
19196681 2009
6
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 57 61 54
18946062 2008
7
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. 61 57 54
18275280 2008
8
Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. 57 61
16247433 2005
9
Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia. 61 42
33020578 2020
10
The global impact of Aspergillus infection on COPD. 61 42
32912168 2020
11
Human dectin-1 deficiency and mucocutaneous fungal infections. 6
19864674 2009
12
TLR polymorphisms and the risk of invasive fungal infections. 57
18946070 2008
13
Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. 57
11470510 2001
14
Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. 42
33149181 2020
15
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. 54 61
20413160 2010
16
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. 54 61
19827955 2009
17
Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. 61 54
18718399 2008
18
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. 61 54
17335555 2007
19
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. 54 61
17311505 2007
20
Chemokines in allergic aspergillosis--from animal models to human lung diseases. 61 54
17168792 2006
21
[Clinical analysis of chronic pulmonary aspergillosis and discovery of an elastase inhibitor]. 61 54
16940951 2006
22
[A case of idiopathic pulmonary upper lobe fibrosis complicated by invasive pulmonary aspergillosis]. 54 61
12772600 2003
23
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]. 61 54
11979751 2002
24
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. 61 54
11474427 2001
25
Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. 54 61
11500084 2001
26
A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. 61 54
11499676 2001
27
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. 61 54
11254642 2001
28
Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. 61 54
10878372 2000
29
[Aspergillosis: Mechanisms of pathogenicity implicated and approach to laboratory diagnosis.]. 54 61
17655396 1998
30
Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. 61 54
9367408 1997
31
Polymerase chain reaction amplification of Asp f I and alkaline protease genes from fungus balls: clinical application in pulmonary aspergillosis. 61 54
9058095 1997
32
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation]. 54 61
8691669 1996
33
[Protective effect of human macrophage colony-stimulating factor on fungal infection (2). In vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage]. 61 54
7602192 1995
34
Western blot detection of IgG anti-Aspergillus fumigatus elastase in sera of patients with aspergillosis. 61 54
7965494 1994
35
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. 54 61
1452348 1992
36
Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease. 54 61
1655460 1991
37
[Aspergillus mastoiditis in infected granulomatosis--a case report]. 61 54
2165779 1990
38
Trends of pulmonary fungal infections from 2013 to 2019: an AI-based real-world observational study in Guangzhou, China. 61
33620282 2021
39
Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. 61
33748741 2021
40
TREM1 regulates antifungal immune responses in invasive pulmonary aspergillosis. 61
33525982 2021
41
Sensitization to A fumigatus in subjects with non-cystic fibrosis bronchiectasis. 61
33332671 2021
42
Video-assisted thoracic surgery for a case of chronic progressive pulmonary aspergillosis undergoing haemodialysis complicated by anorexia nervosa: a case report. 61
33664960 2021
43
Impact of domestic mould exposure on Aspergillus biomarkers and lung function in patients with chronic obstructive pulmonary disease. 61
33577771 2021
44
Aspergillus isolation in nontuberculous mycobacterial pulmonary disease: Associated with antimycobacterial treatment initiation but not response. 61
33611086 2021
45
Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients. 61
32880845 2021
46
When should we use corticosteroids in severe community-acquired pneumonia? 61
33394726 2021
47
Unusual case presentation of fungal ball infection causing diabetes insipidus and seizure disorder. 61
33537110 2021
48
Risk factors for chronic pulmonary aspergillosis in post-TB patients. 61
33762078 2021
49
COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. 61
33569857 2021
50
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. 61
33355949 2021
Sources

Variations for Aspergillosis

About this section

ClinVar genetic disease variations for Aspergillosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CLEC7A NM_197947.3(CLEC7A):c.714T>G (p.Tyr238Ter) SNV risk factor 4466 rs16910526 GRCh37: 12:10271087-10271087
GRCh38: 12:10118488-10118488
2 CLEC1A NM_016511.4(CLEC1A):c.77G>C (p.Gly26Ala) SNV risk factor 590287 rs2306894 GRCh37: 12:10251445-10251445
GRCh38: 12:10098846-10098846
Sources

Expression for Aspergillosis

About this section
Search GEO for disease gene expression data for Aspergillosis.
Sources

Pathways for Aspergillosis

About this section

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.07 TNF TLR9 TLR4 TLR2 PTX3 MBL2
2
ERK Signaling 63
Show member pathways
 13.87 TNF IL5 IL4 IL1B IL10 CSF3
3
PEDF Induced Signaling 63
Show member pathways
 13.77 TNF TLR4 IL5 IL4 IL1B IL10
4
Akt Signaling 63
Show member pathways
 13.5 TNF TLR9 TLR4 TLR2 IL5 IL4
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.46 TNF IL5 IL4 IL1B IL10 IFNG
6
PAK Pathway 63
Show member pathways
 13.39 TNF IL5 IL4 IL1B IL10 CSF3
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.32 TNF TLR9 TLR4 TLR2 SFTPD MBL2
8
PI3K-Akt signaling pathway 36
Show member pathways
 13.05 TNF TLR4 TLR2 IL4 CSF3 CSF1
9
Allograft rejection 36 1
Show member pathways
 12.94 TNF IL5 IL4 IL1B IL10 IFNG
10
Measles 36
Show member pathways
 12.91 TNF TLR9 TLR4 TLR2 IL1B IFNG
11
IL-2 Pathway 63
Show member pathways
 12.9 TNF TLR9 TLR4 TLR2 IL4 IL1B
12
Herpes simplex virus 1 infection 36
12.84 TNF TLR9 TLR2 IL1B IFNG
13
Salmonella infection (KEGG) 36
Show member pathways
 12.79 TNF TLR9 TLR4 TLR2 IL1B
14
NF-KappaB Family Pathway 63
Show member pathways
 12.76 TNF TLR9 TLR4 TLR2 IL1B
15
Th17 cell differentiation 36
Show member pathways
 12.74 TNF TLR4 TLR2 IL5 IL4 IL1B
16
RANK Signaling in Osteoclasts 63
Show member pathways
 12.71 TNF IL1B IL10 IFNG CSF1
17
T cell receptor signaling pathway 36
Show member pathways
 12.71 TNF TLR9 TLR4 TLR2 IL5 IL4
18
NF-kappaB Signaling 4
12.69 TNF TLR9 TLR2 IL4 IL1B IL10
19
TRAF Pathway 63
Show member pathways
 12.66 TNF TLR9 TLR4 TLR2 IL1B
20
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.52 TNF TLR9 TLR4 TLR2 IL1B
21
JAK-STAT signaling pathway 36
Show member pathways
 12.51 IL5 IL4 IL10 IFNG CSF3
22
IL-17 Family Signaling Pathways 64
Show member pathways
 12.46 TNF TLR2 IL5 IL4 IL1B IFNG
23
Selenium Micronutrient Network 1
Show member pathways
 12.44 TNF IL4 IL1B IFNG CSF1
24
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.44 TNF IL10 CSF1 CCR6 CCL3
25
Toxoplasmosis 36
Show member pathways
 12.41 TNF TLR4 TLR2 IL4 IL1B IL10
26
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.38 TNF IL5 IL4 IL1B IL10 IFNG
27
C-type lectin receptor signaling pathway 36
Show member pathways
 12.33 TNF TLR9 IL1B IL10 CLEC7A
28
Tuberculosis 36
12.33 TNF TLR9 TLR4 TLR2 IL1B IL10
29
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.32 TNF TLR9 TLR4 TLR2
30
Colorectal Cancer Metastasis 63
12.3 TNF TLR9 TLR4 TLR2 IFNG
31
IL-1 Family Signaling Pathways 64
Show member pathways
 12.28 TNF TLR2 IL1B CFTR
32
Necroptosis 36
Show member pathways
 12.26 TNF TLR4 IL1B IFNG
33
Phagosome 36
12.25 TLR4 TLR2 SFTPD MBL2 CLEC7A
34
Bacterial infections in CF airways 23
Show member pathways
 12.19 TNF TLR9 TLR4 TLR2 SFTPD IL4
35
Yersinia infection 36
12.16 TNF TLR4 IL1B IL10
36
MAPK Pathway 69
Show member pathways
 12.15 TLR9 TLR4 TLR2 IL5 IL1B
37
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.14 TNF IL5 IL4 IL10 IFNG CSF3
38
Spinal Cord Injury 1
12.13 TNF TLR4 IL4 IL1B IFNG
39
Amoebiasis 36
12.1 TNF TLR4 TLR2 IL1B IL10 IFNG
40
Interleukin-4 and 13 signaling 65
12.08 TNF IL4 IL1B IL10
41
Hematopoietic cell lineage 36
12.08 TNF IL5 IL4 IL1B CSF3 CSF1
42
IL12-mediated signaling events 1
Show member pathways
 12.07 IL4 IL1B IFNG CCL3
43
Th17 Differentiation Pathway 64
Show member pathways
 12.02 TLR9 TLR4 TLR2 IL4 IL1B IFNG
44
Rheumatoid arthritis 36
11.97 TNF TLR4 TLR2 IL1B IFNG CSF1
45
Phagocytosis of Microbes 63
11.93 TLR9 TLR4 TLR2 CLEC7A
46
Dendritic Cells Developmental Lineage Pathway 64
11.9 TNF TLR9 IL1B IL10 IFNG CSF1
47
Pertussis 36
11.88 TNF TLR4 IL1B IL10
48
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 TNF IL5 IL4 IFNG
49
Th1 Differentiation Pathway 64
Show member pathways
 11.86 TNF TLR9 TLR4 TLR2 IL1B IL10
50
Glucocorticoid receptor regulatory network 1
11.84 IL5 IL4 IFNG
Sources

GO Terms for Aspergillosis

About this section

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF TLR9 SFTPD PTX3 MBL2 IL5
2 cell surface GO:0009986 9.76 TNF TLR4 TLR2 MBL2 ELANE CLEC7A
3 extracellular space GO:0005615 9.44 TNF SFTPD PTX3 MBL2 IL5 IL4

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 TLR9 TLR4 TLR2 IL5 IL4 IL1B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.29 TNF TLR9 TLR4 TLR2 IL4 IL10
3 immune system process GO:0002376 10.24 TLR9 TLR4 TLR2 SFTPD MBL2 CSF1
4 innate immune response GO:0045087 10.21 TLR9 TLR4 TLR2 SFTPD PTX3 MBL2
5 positive regulation of cell proliferation GO:0008284 10.19 IL5 IL4 IL1B IFNG CSF3 CSF1
6 defense response to bacterium GO:0042742 10.12 TNF TLR9 TLR4 SFTPD MBL2 IL10
7 positive regulation of cell migration GO:0030335 10.1 IL4 IL1B CSF1 CLEC7A CCL3
8 positive regulation of gene expression GO:0010628 10.1 TNF TLR9 TLR4 TLR2 IL4 IL1B
9 response to lipopolysaccharide GO:0032496 10.06 TLR4 TLR2 IL1B IL10 ELANE
10 cytokine-mediated signaling pathway GO:0019221 10.06 TNF IL5 IL4 IL1B IL10 CSF3
11 cellular response to lipopolysaccharide GO:0071222 10.05 TNF TLR4 IL1B IL10 CSF3
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.05 TNF TLR9 TLR4 TLR2 IL1B
13 positive regulation of DNA-binding transcription factor activity GO:0051091 10.02 TNF IL5 IL1B IL10 CSF3
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 10 TNF TLR9 TLR4 TLR2 IL1B
15 positive regulation of JNK cascade GO:0046330 9.98 TNF TLR9 TLR4 IL1B
16 positive regulation of interferon-gamma production GO:0032729 9.98 TNF TLR9 TLR4 IL1B CLEC7A
17 negative regulation of interleukin-6 production GO:0032715 9.97 TNF TLR9 TLR4 IL10
18 positive regulation of tumor necrosis factor production GO:0032760 9.97 TLR9 TLR4 TLR2 IFNG CLEC7A CCL3
19 positive regulation of interleukin-1 beta production GO:0032731 9.96 TNF TLR4 IFNG CLEC7A CCL3
20 negative regulation of tumor necrosis factor production GO:0032720 9.93 TLR4 IL4 IL10
21 regulation of insulin secretion GO:0050796 9.93 TNF IL1B IFNG
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 TNF IL4 IFNG
23 cellular response to organic cyclic compound GO:0071407 9.93 TNF IL1B CCL3
24 toll-like receptor signaling pathway GO:0002224 9.93 TLR9 TLR4 TLR2 SFTPD
25 positive regulation of interleukin-12 production GO:0032735 9.93 TLR9 TLR4 TLR2 IFNG CLEC7A
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TNF TLR9 TLR4
27 humoral immune response GO:0006959 9.92 TNF IFNG CCR6
28 positive regulation of B cell proliferation GO:0030890 9.92 TLR9 TLR4 IL5 IL4
29 positive regulation of chemokine production GO:0032722 9.92 TNF TLR9 TLR4 TLR2 IFNG
30 positive regulation of protein complex assembly GO:0031334 9.91 TNF IFNG CLEC7A
31 positive regulation of cytokine production GO:0001819 9.91 TNF IL10 IFNG
32 microglial cell activation GO:0001774 9.91 TNF TLR2 IL4 IFNG
33 positive regulation of interleukin-10 production GO:0032733 9.91 TLR9 TLR4 TLR2 IL4 CLEC7A
34 positive regulation of phagocytosis GO:0050766 9.91 TNF SFTPD PTX3 IL1B IFNG CLEC7A
35 negative regulation of interleukin-8 production GO:0032717 9.9 TLR9 IL10 ELANE
36 protein kinase B signaling GO:0043491 9.89 TNF IL1B CCL3
37 positive regulation of interferon-beta production GO:0032728 9.89 TLR9 TLR4 TLR2
38 positive regulation of JAK-STAT cascade GO:0046427 9.88 TNF IL5 IL10
39 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.88 TLR9 TLR4 TLR2
40 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TNF TLR4 TLR2 IL1B CCL3
41 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.87 TLR9 TLR4 TLR2 IFNG
42 positive regulation of inflammatory response GO:0050729 9.87 TNF TLR9 TLR4 TLR2 IL1B IFNG
43 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.86 TNF TLR4 CLEC7A
44 negative regulation of osteoclast differentiation GO:0045671 9.86 TLR4 IL4 CCL3
45 positive regulation of osteoclast differentiation GO:0045672 9.85 TNF IFNG CSF1
46 positive regulation of immunoglobulin production GO:0002639 9.85 TLR9 IL5 IL10
47 positive regulation of MHC class II biosynthetic process GO:0045348 9.85 TLR4 IL4 IL10 IFNG
48 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF TLR4 PTX3 IL1B IFNG CLEC7A
49 inflammatory response GO:0006954 9.85 TNF TLR9 TLR4 TLR2 PTX3 IL5
50 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.84 TNF IL1B IFNG

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TNF TLR9 TLR4 TLR2 SFTPD PTX3
2 carbohydrate binding GO:0030246 9.71 SFTPD MBL2 CLEC7A CLEC1A
3 lipopolysaccharide receptor activity GO:0001875 9.37 TLR4 TLR2
4 growth factor activity GO:0008083 9.35 IL5 IL4 IL10 CSF3 CSF1
5 pattern recognition receptor activity GO:0038187 9.33 TLR9 TLR2 CLEC7A
6 cytokine activity GO:0005125 9.28 TNF IL5 IL4 IL1B IL10 IFNG
7 (1->3)-beta-D-glucan binding GO:0001872 9.26 PTX3 CLEC7A
Sources

Sources for Aspergillosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....